Reading APYX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track APYX free→Reading APYX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track APYX free→QuarterlyIQ Insights · APYX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition On May 7, 2026, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the first quarter ended March 31, 2026. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under
Results of Operations and Financial Condition On March 10, 2026, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the fourth quarter and year ended December 31, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under
Results of Operations and Financial Condition On January 12, 2026, Apyx Medical Corporation (the “Company”) issued a press release reporting on its preliminary revenue results for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to
Entry into a Material Definitive Agreement. On November 18, 2025, Apyx Medical Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lucid Capital Markets, LLC (the “Underwriter”) pursuant to which the Company will issue and sell to the Underwriter pursuant to the Underwriting Agreement 2,762,431 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) at an offering price of $3.62 and grant to the Underwriter an o…
Results of Operations and Financial Condition On November 6, 2025, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the third quarter ended September 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under
Results of Operations and Financial Condition On August 7, 2025, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the second quarter ended June 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under
Results of Operations and Financial Condition On May 8, 2025, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the first quarter ended March 31, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under
Results of Operations and Financial Condition On March 13, 2025, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the fourth quarter and year ended December 31, 2024. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 31, 2025, Apyx Medical Corporation (the “Company”), following the prior announcement that it had appointed Shawn Roman as its Chief Operating Officer, the Company entered into an Employment Agreement with Mr. Roman (the “Employment Agreement”), effective January 28, 2025 (the “Effective Date”). Pursuant to the terms of the Employment Agr…
Importance-ranked changes since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.